Type II, glycoengineered anti-CD20 IgG1 monoclonal antibody that depletes CD20+ B cells via ADCC/ADCP and direct cell death, reducing anti-PLA2R autoantibodies.
Type II, glycoengineered anti-CD20 IgG1 that binds CD20 on B cells and depletes CD20+ B cells via enhanced Fc gamma RIII–mediated ADCC/ADCP and direct cell death, reducing pathogenic anti-PLA2R autoantibodies.
Obinutuzumab binds CD20 on B cells; its glycoengineered Fc engages FcγRIIIa to trigger NK-cell ADCC and macrophage ADCP, and CD20 ligation induces direct caspase-independent cell death (limited CDC).
Rabbit polyclonal anti-thymocyte globulin that depletes T cells to prevent rejection and GVHD.
Rabbit polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, producing immunosuppression to prevent rejection and GVHD.
Polyclonal antibodies in ATG bind CD18 on T cells, triggering complement-dependent lysis, antibody-dependent cellular cytotoxicity, and apoptosis to deplete target-expressing cells.
Anti-CD20 monoclonal antibody that depletes CD20+ B cells via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis.
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on B cells and depletes CD20+ cells via antibody‑dependent cellular cytotoxicity, complement‑dependent cytotoxicity, and induction of apoptosis.
Rituximab binds CD20 on B cells and triggers Fc-mediated ADCC by NK cells/macrophages and complement-dependent cytotoxicity; it can also induce apoptosis upon CD20 cross‑linking.
Anti-CD38 monoclonal antibody mediating CDC, ADCC, ADCP, and apoptosis, and depleting CD38+ immunosuppressive cells.
Human IgG1k anti-CD38 monoclonal antibody that binds CD38 on malignant plasma cells and other CD38+ cells, inducing complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and apoptosis; also depletes CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs), enhancing antitumor immunity.
Anti-CD38 IgG1 binds CD38 on target cells and triggers Fc-mediated complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) by NK cells, antibody-dependent cellular phagocytosis (ADCP) by macrophages, and can induce apoptosis upon crosslinking.
Humanized anti-CD20 monoclonal antibody used as a high-efficacy disease-modifying therapy (DMT) to deplete CD20+ B cells in multiple sclerosis.
Humanized anti-CD20 IgG1 monoclonal antibody that binds CD20 on B lymphocytes and depletes them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity, reducing B-cell–mediated immune activity in multiple sclerosis.
Ocrelizumab binds CD20 on B cells and triggers complement-dependent cytotoxicity and Fc-mediated ADCC (and phagocytosis), leading to lysis/depletion of CD20+ cells.